Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ESSEX BIO-TECHNOLOGY LIMITED

億 勝 生 物 科 技 有 限 公 司

(Incorporated in the Cayman Islands with limited liability)
(Stock code: 8151)

PROFIT WARNING

This announcement is made pursuant to Rule 17.10 of the GEM Listing Rules.

The Board wishes to inform the shareholders of the Company and potential investors that it is expected that the operating results of the Group for the three months ended 31 March 2009 may experience a material decline as compared to the corresponding period in 2008. Based on information currently available, the Board considers that such decline is mainly attributable to the volatility of prices of raw materials for agricultural fertilisers which had a negative impact on the Group's agricultural business, whilst the pharmaceutical business of the Group is still contributing positively.

Shareholders of the Company and potential investors should exercise caution when dealing in the shares of the Company.

This announcement is made pursuant to Rule 17.10 of the Rules Governing the Listing of Securities on The Growth Enterprise Market of The Stock Exchange of Hong Kong Limited (the "GEM Listing Rules").

The board of Directors (the "Board") of Essex Bio-Technology Limited (the "Company") wishes to inform the shareholders of the Company and potential investors that it is expected that the operating results of the Company and its subsidiaries (collectively the "Group") for the three months ended 31 March 2009 may experience a material decline as compared to the corresponding period in 2008. Based on information currently available, the Board considers that such decline is mainly attributable to the volatility of prices of raw materials for agricultural fertilisers which had a negative impact on the Group's agricultural business, whilst the pharmaceutical business of the Group is still contributing positively.

As the Company is still in the process of finalizing the quarterly results for the three months ended 31 March 2009, the information contained in this announcement is only based on the preliminary assessment by the Company's management according to the consolidated management accounts of the Group which have not been reviewed by the Company's auditors. The preliminary assessment of the Group's operating results is subject to further review by the management on the final results which are being prepared. Shareholders of the Company and potential investors should read the Group's quarterly results announcement for the three months ended 31 March 2009 carefully, which is expected to be published on 8 May 2009.

Shareholders of the Company and potential investors should exercise caution when dealing in the shares of the Company.

By order of the Board
Essex Bio-Technology Limited
Zhong Sheng
Executive Director

Hong Kong, 28 April 2009

Executive directors of the Company as at the date of this announcement are Mr Ngiam Mia Je Patrick, Mr Fang Haizhou and Mr Zhong Sheng. Independent non-executive directors of the Company as at the date of this announcement are Mr Fung Chi Ying, Mr Mauffrey Benoit Jean Marie and Ms Yeow Mee Mooi.

This announcement, for which the directors of the Company collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The directors of the Company, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief: (i) the information contained in this announcement is accurate and complete in all material respects and not misleading; (ii) there are no other matters the omission of which would make any statement in this announcement misleading; and (iii) all opinions expressed in this announcement have been arrived at after due and careful consideration and are founded on bases and assumptions that are fair and reasonable.

This announcement will remain on the "Latest Company Announcements" page of the GEM website at www.hkgem.com for at least 7 days from the date of its posting and on the website of the Company at www.essexbio.com.